Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 12, 2014, Pages 1415-1421

  McNamara, Deirdre ^a   Leen, Ronan ^a   Seng Lee, Chun ^a   Shearer, Nikki ^a   Crotty, Paul ^a   Neary, Paul ^a   Walsh, Paul ^a   Boran, Gerard ^a   O'Morain, Colm ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Colorectal cancer; Faecal immunological test; Screening

Indexed keywords

ADENOMA; ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; FECAL IMMUNOLOGICAL TEST; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT PARTICIPATION; PREDICTIVE VALUE; PRIORITY JOURNAL; ADENOMATOUS POLYPS; AGE; BLOOD; CARCINOMA; COLONIC POLYPS; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; EARLY DIAGNOSIS; IMMUNOLOGICAL PROCEDURES; IRELAND; MIDDLE AGED; OCCULT BLOOD; PATHOLOGY; PATIENT ATTITUDE; PROCEDURES; PROGRAM EVALUATION; SEX DIFFERENCE;

ADENOMATOUS POLYPS; AGE FACTORS; AGED; CARCINOMA; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOLOGIC TESTS; IRELAND; MALE; MIDDLE AGED; OCCULT BLOOD; PATIENT ACCEPTANCE OF HEALTH CARE; PREDICTIVE VALUE OF TESTS; PROGRAM EVALUATION; SEX FACTORS;

EID: 84927698693     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000207     Document Type: Article

References (36)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16:481-488.
2. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010; 21:1323-1360.
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46:765-781.
4. Heresbach D, Manfredi S, D'halluin PN, Bretagne JF, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 2006; 18:427-433.
5. Hewiston P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the faecal occult blood. Am J Gastroenterol 2008; 103:1541-1549.
6. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 2008; 44:2254-2258.
7. Oort FA, Terhaar Sive Droste JS, Van Der Hulst RW, Van Heukelem HA, Loffeld RJ, Wesdorp IC, et al. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment Pharmacol Ther 2010; 31:432-439.
8. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59:62-68.
9. McNamara D, Qasim A, Lee N, Condon C, O'Morain C. Round one of the Adelaide and Meath Hospital/Trinity College Colorectal Cancer Screening Programme: programme report and analysis based on established international key performance indices. Ir J Med Sci 2011; 180:549-552.
10. Crotta S, Castiglione G, Grazzini G, Valle F, Mosconi S, Rosset R. Feasibility study of colorectal cancer screening by immunochemical faecal occult blood testing: results in a northern Italian community. Eur J Gastroenterol Hepatol 2004; 16:33-37.
11. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366:687-696.
12. Terhaar sive Droste JS, Oort FA, van der Hulst RW, van Heukelem HA, Loffeld RJ, van Turenhout ST, et al. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for earlystage colorectal cancers. Cancer Epidemiol Biomarkers Prev 2011; 20:272-280.
13. Van Roon AH, Wilschut JA, Hol L, van Ballegooijen M, Reijerink JC, 't Mannetje H, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2011; 9:333-339.
14. Steele RJ, McClements PL, Libby G, Black R, Morton C, Birrell J, et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009; 58:530-535.
15. Weller D, Coleman D, Robertson R, Butler P, Melia J, Campbell C, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer 2007; 97:1601-1605.
16. Denters MJ, Deutekom M, Bossuyt PM, van Rijn AF, Fockens P, Dekker E. Involvement of previous non-participants cannot fully compensate for lower participation in a second round of FIT-screening. Cancer Epidemiol 2013; 37:330-335.
17. Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 2012; 142:497-504.
18. Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 2012; 10:633-638.
19. Parente F, Boemo C, Ardizzoia A, Costa M, Carzangia P, IIardo A, et al. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Endoscopy 2013; 45:27-34.
20. Byrne M, O'Reilly S. Guidelines for quality assurance in colorectal screening. 1st ed. Dublin: National Cancer Screening Service; 2012.
21. European Colorectal Cancer Screening Guidelines Working Group. von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013; 45:51-59.
22. Seeff LC, Nadel MR, Klabunde CN, Thompson T, Shapiro JA, Vernon SW, Coates RJ. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer 2004; 100:2093-2103.
23. Ananthakrishnan AN, Schellhase KG, Sparapani RA, Laud PW, Neuner JM. Disparities in colon cancer screening in the Medicare population. Arch Intern Med 2007; 167:258-264.
24. Ko HH, Zhang H, Telford JJ, Enns R. Factors influencing patient satisfaction when undergoing endoscopic procedures. Gastrointest Endosc 2009; 69:883-891.
25. Singh SM, Paszat LF, Li C, He J, Vinden C, Rabeneck L. Association of socioeconomic status and receipt of colorectal cancer investigations: a population-based retrospective cohort study. CMAJ 2004; 171:461-465.
26. Ioannou GN, Chapko MK, Dominitz JA. Predictors of colorectal cancer screening participation in the United States. Am J Gastroenterol 2003; 98:2082-2091.
27. Frederiksen BL, Jørgensen T, Brasso K, Holten I, Osler M. Socioeconomic position and participation in colorectal cancer screening. Br J Cancer 2010; 103:1496-1501.
28. Van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006; 101:343-350.
29. Dik VK, Moons LM, Siersema PD. Endoscopic innovations to increase the adenoma detection rate during colonoscopy. World J Gastroenterol 2014; 20:2200-2211.
30. Digby J, McDonald PJ, Strachan JA, Libby G, Steele RJ, Fraser CG. Use of a faecal immunochemical test narrows current gaps in uptake for sex, age and deprivation in a bowel cancer screening programme. J Med Screen 2013; 20:80-85.
31. Hassan C, Giorgi Rossi P, Camilloni L, Rex DK, Jimenez-Cendales B, Ferroni E, et al. HTA Group. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012; 36:929-940.
32. Khalid-de Bakker C, Jonkers D, Smits K, Mesters I, Masclee A, Stockbrügger R. Participation in colorectal cancer screening trials after firsttime invitation: a systematic review. Endoscopy 2011; 43:1059-1086.
33. Kapidzic A, Grobbee EJ, Hol L, van Roon AH, van Vuuren AJ, SpijkerW, et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 2014; 109:1257-1264.
34. Van Roon AH, Goede SL, van Ballegooijen M, van Vuuren AJ, Looman CW, Biermann K, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013; 62:409-415.
35. Oort FA, van Turenhout ST, Coupé VM, van der Hulst RW,Wesdorp EI, Terhaar sive Droste JS, et al. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer 2011; 11:434.
36. Goede SL, van Roon AH, Reijerink JC, van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JD, et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2013; 62:727-734.